查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790499

Erleada 市場規模、佔有率和趨勢分析報告：按類型、分銷管道、地區和細分市場預測，2025 年至 2033 年

Erleada Market Size, Share & Trends Analysis Report By Type (Branded, Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

阿萊達市場摘要

2024 年全球 ERDA 市場價值估計為 29.99 億美元，預計到 2033 年將達到 61.66 億美元，2025 年至 2033 年的複合年成長率為 7.99%。 ERDA 產業越來越注重聯合治療，以改善轉移性去勢抗性前列腺癌 (mCRPC) 的治療效果。

計劃於 2027 年完成的 III 期臨床試驗（例如 NCT02257736）正在評估阿帕魯胺與醋酸Abiraterone和潑尼鬆的聯合用藥效果，以建立協同作用並探索潛在的適應症擴展。利用臨床數據，例如 SPARTAN 試驗中轉移風險降低 70%（HR 0.28），相關人員可以加強與付款人的談判並保持市場吸引力。重視聯合治療加強了 Erleada 對抗新興學名藥的地位，例如 Zydus Lifesciences 的阿帕魯胺片，該片於 2025 年 3 月獲得美國 FDA核准，威脅到 Erleada 的市場獨佔權。強生公司的專利涵蓋某些製劑直至 2038 年，為患者提供法律保護，但訴訟的可能性仍然令人擔憂。

市場受到價值導向醫療日益普及的影響，尤其是像聯邦醫療保險（Medicare）這樣的美國支付機構，他們更青睞那些經證實具有長期效益的治療方法。阿帕魯胺的臨床證據，包括使用TITAN後死亡風險降低33%（HR 0.67），正在產生現實影響，因為聯邦醫療保險優勢計劃報告稱，到2024年，與替代療法相比，非去勢抵抗性前列腺癌（nmCRPC）患者的住院率降低了10%。透過產生現實證據來證明成本效益，並投資於醫療服務提供者關於阿帕魯胺給藥的教育，相關人員可以增強市場韌性，促進其應用，並減輕學名藥競爭的影響。

ERLEAD® 產業受益於人們對早期前列腺癌篩檢認知的提升，並受益於美國預防服務工作組 (美國 Preventive Services Task Force) 等舉措的支持，從而提高了診斷率並擴大了患者覆蓋範圍。這一趨勢與 ERLEAD® 的標靶機制相結合，與精準醫療的轉型相契合，並為滿足尚未滿足的需求提供了機會。例如，2023 年核准的每日一次 240 毫克錠劑將提高患者的依從性並增強 ERLEAD® 的競爭地位。相關人員應專注於利用這些進步，在不斷變化的治療模式中保持市場領先地位。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章 早期讀者市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 早期閱讀器市場：類型業務分析

  • 2024 年及 2033 年各類型市場佔有率
  • 類型細分儀表板
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 品牌
  • 非專利的

第5章 早期閱讀器市場：通路業務分析

  • 2024年及2033年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥局
  • 其他

第6章 早期領先市場：區域評估與趨勢分析

  • 2024 年及 2033 年區域市場佔有率分析
  • 區域市場儀表板
  • 2021-2033年市場規模與預測趨勢分析
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Janssen Biotech, Inc.
    • Zydus Lifesciences
Product Code: GVR-4-68040-662-9

Erleada Market Summary

The global erleada market size was estimated at USD 2,999 million in 2024 and is projected to reach USD 6,166 million by 2033, growing at a CAGR of 7.99% from 2025 to 2033. The erleada industry is increasingly shaped by the push toward combination therapies to enhance treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC).

Phase 3 trials, such as NCT02257736, set to conclude in 2027, are evaluating Apalutamide alongside Abiraterone acetate and Prednisone to establish synergistic effects and potentially expand indications. By leveraging clinical data, like the SPARTAN trial's 70% reduction in metastasis risk (HR 0.28), stakeholders can strengthen payer negotiations and maintain market traction. The emphasis on combination therapies strengthens Erleada's position against emerging generics, like Zydus Lifesciences' Apalutamide Tablets, which received USFDA approval in March 2025, threatening Erleada's market exclusivity. Johnson & Johnson's patents, covering specific formulations until 2038, offer legal protection, but the potential for litigation remains a concern.

The market is influenced by the growing adoption of value-based care, particularly among U.S. payers like Medicare, who favor therapies with proven long-term benefits. Erleada's clinical evidence, including TITAN's 33% mortality risk reduction (HR 0.67), has driven real-world impact, with Medicare Advantage plans reporting a 10% reduction in nmCRPC patient hospitalizations in 2024 compared to alternatives. Stakeholders can enhance market resilience by generating real-world evidence to demonstrate cost-effectiveness and investing in healthcare provider education on Apalutamide's administration to boost adoption and mitigate the impact of generic competition.

The erleada industry benefits from keen awareness of early prostate cancer screening, supported by initiatives like those from the U.S. Preventive Services Task Force, which have increased diagnosis rates and expanded the eligible patient pool. This trend, coupled with Erleada's targeted mechanism, aligns with the shift toward precision medicine, offering opportunities to address unmet needs. For instance, the 2023 approval of a 240 mg once-daily tablet improved patient compliance, reinforcing Erleada's competitive positioning. Stakeholders should focus on leveraging these advancements to maintain market leadership amidst evolving treatment paradigms.

Global Erleada Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global erleada market report based on type, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Erleada Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Erleada Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2021 - 2033 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic Market, 2021 - 2033 (USD Million)

Chapter 5. Erleada Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Erleada Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Erleada Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Janssen Biotech, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Zydus Lifesciences
      • 7.6.1.1. Overview
      • 7.6.1.2. Financial Performance
      • 7.6.1.3. Product Benchmarking
      • 7.6.1.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Erleada market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 8 North America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S. Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 12 Canada Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 17 Europe Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 19 UK Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 21 Germany Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 23 France Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 25 Italy Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Spain Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 29 Norway Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 31 Denmark Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 33 Sweden Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 38 Japan Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 40 China Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 42 India Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 44 Australia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 46 South Korea Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 48 Thailand Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Latin America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 53 Brazil Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Argentina Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 60 South Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 64 UAE Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Erleada market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Erleada market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Erleada market dynamics
  • Fig. 12 Erleada market: Porter's five forces analysis
  • Fig. 13 Erleada market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Branded market, 2021 - 2033 (USD Million)
  • Fig. 16 Generic market, 2021 - 2033 (USD Million)
  • Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 18 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 19 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Erleada market revenue, by region
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America Erleada market, 2021 - 2033 (USD Million)
  • Fig. 24 US country dynamics
  • Fig. 25 US Erleada market, 2021 - 2033 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada Erleada market, 2021 - 2033 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico Erleada market, 2021 - 2033 (USD Million)
  • Fig. 30 Europe Erleada market, 2021 - 2033 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK Erleada market, 2021 - 2033 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany Erleada market, 2021 - 2033 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France Erleada market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy Erleada market, 2021 - 2033 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain Erleada market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway Erleada market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden Erleada market, 2021 - 2033 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark Erleada market, 2021 - 2033 (USD Million)
  • Fig. 47 Asia Pacific Erleada market, 2021 - 2033 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan Erleada market, 2021 - 2033 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China Erleada market, 2021 - 2033 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India Erleada market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia Erleada market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea Erleada market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand Erleada market, 2021 - 2033 (USD Million)
  • Fig. 60 Latin America Erleada market, 2021 - 2033 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Erleada market, 2021 - 2033 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Erleada market, 2021 - 2033 (USD Million)
  • Fig. 65 MEA Erleada market, 2021 - 2033 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Erleada market, 2021 - 2033 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia Erleada market, 2021 - 2033 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE Erleada market, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait Erleada market, 2021 - 2033 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework